GO:0042197 halogenated hydrocarbon metabolic process

Halogenated hydrocarbons are organic molecules in which one or more hydrogen atoms have been replaced by a halogen atom, most commonly chlorine, bromine, fluorine or iodine. These compounds include industrial solvents, pesticides, refrigerants, flame retardants and a wide range of natural products, and many of them are persistent environmental contaminants [3,5]. The Gene Ontology term GO:0042197, halogenated hydrocarbon metabolic process, captures the chemical reactions and pathways that convert these molecules, whether through microbial degradation, mammalian biotransformation or abiotic transformation [1,4]. Understanding this process is central to environmental microbiology, toxicology and drug metabolism, because the same carbon-halogen bond that makes a compound useful industrially also makes it resistant to breakdown and potentially hazardous to human health [2,7]. Research on halogenated hydrocarbon metabolism has revealed that microorganisms have evolved a remarkable diversity of dehalogenating enzymes, including hydrolytic dehalogenases, reductive dehalogenases, monooxygenases and dioxygenases [1,4,8]. These enzymes allow bacteria to use halogenated compounds as carbon sources, electron acceptors or co-metabolic substrates, and they underpin bioremediation strategies for contaminated soils and groundwater [4,8]. In mammals, halogenated hydrocarbons are metabolized by cytochrome P450 enzymes and glutathione S-transferases, which can either detoxify the parent compound or generate reactive intermediates that damage cellular macromolecules [2,7]. The balance between activation and detoxification is a key determinant of susceptibility to halogenated solvent toxicity [2,7]. For researchers, GO:0042197 provides a structured framework for annotating genes and pathways involved in halogen metabolism across species. It connects environmental microbiology, where dehalogenation supports bioremediation [4,8], with human toxicology, where halogenated compounds are linked to liver, kidney and neurological injury [2,7]. The term also intersects with drug discovery, since many pharmaceuticals contain halogen atoms and their metabolic fate influences efficacy and safety. This article reviews the definition, mechanism, key genes, disease relevance and research methods for GO:0042197, with a focus on how CRISPR-based models can accelerate functional studies.

GO:0042197, halogenated hydrocarbon metabolic process, is defined as the chemical reactions and pathways involving halogenated hydrocarbons, which are compounds derived from hydrocarbons by replacing one or more hydrogen atoms with halogen atoms such as fluorine, chlorine, bromine or iodine. In practice, this term covers both the breakdown of halogenated compounds, often called dehalogenation, and the broader metabolic transformations that convert them into other products [1,4]. The synonym halogenated hydrocarbon metabolism is used interchangeably. The process is a biological_process in the Gene Ontology and is relevant to microbial degradation, mammalian biotransformation and environmental fate studies [1,4,8].

GO:0042197 is important because halogenated hydrocarbons are widespread environmental contaminants and industrial chemicals whose persistence and toxicity depend on their metabolic fate [3,5]. Microbial dehalogenation determines whether pollutants such as chlorinated solvents and pesticides are degraded in soil and groundwater or accumulate in food chains [1,4]. In humans, the same metabolic pathways can activate halogenated compounds to reactive intermediates that cause tissue injury, or detoxify them through glutathione conjugation [2,7]. Understanding these processes supports bioremediation, risk assessment and drug metabolism studies [4,6,8].

The following genes and gene families encode enzymes and proteins that catalyze or regulate halogenated hydrocarbon metabolic processes across bacteria, fungi and mammals.

Halogenated hydrocarbon metabolic process is regulated at multiple levels. In bacteria, dehalogenase genes are often controlled by specific transcriptional regulators that respond to halogenated substrates or their metabolites, allowing induction only when the compound is present [1,4]. Catabolite repression and global regulatory networks can further modulate expression depending on carbon source availability. In mammals, cytochrome P450 enzymes such as CYP2E1 are induced by ethanol and other xenobiotics, altering the rate of halogenated solvent activation [6,7]. Glutathione S-transferase expression is regulated by the Nrf2 antioxidant response pathway, which adjusts detoxification capacity under oxidative stress. These regulatory layers determine whether a halogenated compound is degraded, detoxified or activated to a toxic intermediate [2,6,7].

Many halogenated hydrocarbons, including carbon tetrachloride, chloroform and trichloroethylene, are metabolically activated by cytochrome P450 enzymes to reactive intermediates that cause lipid peroxidation and tissue injury. Glutathione depletion enhances this toxicity, whereas glutathione conjugation can detoxify reactive metabolites. Enzyme induction by ethanol or other agents increases CYP2E1 activity and can exacerbate solvent-induced liver and kidney damage. These mechanisms are relevant to occupational exposure and environmental health risk assessment [2,7].

Persistent halogenated pesticides such as DDT and related organochlorines accumulate in food chains and have been associated with adverse health effects in humans and wildlife [3,5]. Their slow metabolism and lipophilicity lead to bioaccumulation, and their metabolic transformation can produce compounds with different toxicity profiles [3,5]. Understanding microbial and mammalian metabolism of these compounds informs exposure assessment and regulatory decisions [3,4,5].

Glutathione-dependent pathways are central to the detoxification of halogenated compounds, and genetic variation in glutathione S-transferases can influence susceptibility to solvent toxicity. Individuals with reduced detoxification capacity may be at higher risk from exposure to halogenated hydrocarbons. Studying these pathways in cell and animal models helps identify biomarkers of exposure and effect [2,7].

Dehalogenase activity is typically measured by monitoring halide release using ion-selective electrodes or colorimetric assays, or by gas chromatography for volatile substrates [1,4]. These assays allow kinetic characterization of purified enzymes and cell extracts. They are essential for confirming that a candidate gene encodes a functional dehalogenase [1,8].

RNA sequencing and metagenomic analyses identify genes and pathways expressed during growth on halogenated compounds or in contaminated environments [4,8]. These approaches reveal novel dehalogenases and regulatory networks. They are widely used in bioremediation studies to monitor microbial community responses.

Gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry are used to identify and quantify halogenated metabolites and their degradation products [1,7]. These methods track the fate of parent compounds and detect reactive intermediates. They are critical for confirming mineralization and pathway intermediates [4,8].

Cell viability, glutathione depletion and oxidative stress assays are used to assess the toxicity of halogenated compounds and their metabolites in mammalian cells [2,7]. These assays can be combined with CRISPR knockout of metabolic genes to establish causal roles [2,7]. They support risk assessment and mechanistic toxicology.

Researchers studying halogenated hydrocarbon metabolic process-related genes often need to determine whether a candidate gene is causally involved in dehalogenation, detoxification or toxicity. CRISPR-based models provide a precise way to test these hypotheses by deleting, mutating, tagging or overexpressing the genes of interest in relevant bacterial or mammalian systems [1,2,4,7,8].

GO:0042197, halogenated hydrocarbon metabolic process, encompasses the diverse enzymatic strategies that organisms use to transform compounds containing carbon-halogen bonds. From bacterial dehalogenases that drive bioremediation to mammalian cytochrome P450 and glutathione S-transferase pathways that determine toxicity, this process sits at the intersection of environmental microbiology, toxicology and drug metabolism [1,2,4,7,8]. Continued research using CRISPR-based models will clarify the causal roles of specific genes and support the development of better bioremediation and risk assessment strategies [1,4,8].